Two years after its establishment, Geistlich Pharma Australia/NZ, a subsidiary of Swiss company Geistlich Pharma, has taken direct control of the supply of its products in Australia and New Zealand. Up until now, the distribution model for Geistlich's dental range of market-leading bone substitutes, membranes and matrices under brand names Geistlich Bio-Oss®, Geistlich Bio-Gide®, Geistlich Mucograft® and others was split between Geistlich selling direct to specialists and local distributors selling to general dentists.
"As of January 1, 2017, we're now the sole distributor for Geistlich biomaterials in Australia and New Zealand," said Managing Director, Dr Torben Hackl. "We believe we will be able to form closer relationships with our customers who will benefit from the education, service and support we can provide as direct representatives of the manufacturer."
Geistlich is a family-owned company where the knowledge and expertise in bone and collagen processing has been passed to successive generations for more than 165 years. Its products are sold worldwide in more than 70 countries and the name Geistlich stands for the leading brand in regenerative dentistry.
Geistlich Bio-Oss
Geistlich Bio-Oss is the company's flagship product line and this natural bone regeneration material acts as a natural scaffold for new bone formation. The structure of Geistlich Bio-Oss is very similar to human bone, which makes the material very well accepted by the body and highly effective in supporting the body's own regenerative processes. Geistlich Bio-Oss is a natural bone mineral originating from Australian cattle.
Geistlich Bio-Gide
Geistlich Bio-Gide is another market leader and the resorbable collagen membrane is placed over Geistlich Bio-Oss or Bio-Oss Collagen. It acts as a barrier to prevent rapidly growing soft-tissue from invading the space where the new, slower growing bone will form. In addition, Geistlich Bio-Gide promotes good wound healing. Geistlich Bio-Gide membrane is of porcine origin.
Product safety
Geistlich Pharma has an outstanding record for product safety:
- All Geistlich biomaterials are manufactured in Switzerland at the state-of-the-art Geistlich factory. The meticulous selection of natural materials and strictly controlled manufacturing process means Geistlich biomaterials conform to the very highest quality and safety standards;
- Geistlich biomaterials are fully approved for use in Australia and New Zealand (ARTG/WAND listed);
- Sterilisation of end products and a fully documented quality assurance system is the reason why Geistlich Bio-Oss is the only animal bone product approved by the Australian Red Cross Blood Service for blood donors; and
- Geistlich biomaterials have been evaluated in more than 1,000 studies from countries all over the world.
Education
Geistlich believes that education is the key to success and runs a comprehensive CPD calendar throughout the year (visit www.geistlich.com.au/cpd). Encompassing practical hands-on courses as well as theoretical lectures, Geistlich strives to offer an educational program that covers a broad range of indications in the field of regenerative dentistry on different levels. All courses are eligible for the applicable Scientific CPD credit to count towards your quota per CPD cycle.
In 2017, on behalf of the Osteology Foundation, Geistlich has also organised the 1st Australasian Osteology Symposium, which will take place in Melbourne from 2-3 June 2017.
Service and support
Geistlich Pharma Australia/NZ aims to strengthen its collaboration with local clinicians by exceeding customer service expectations and satisfying their regeneration needs for the ultimate benefit of the patient in treatment.
"Since we opened our local subsidiary with dedicated customer service and specialised logistics teams two years ago, we have received a lot of praise and positive comments about our level of service," Dr Hackl added. "And your local Geistlich team is very much looking forward to now being able to look after the regeneration needs of all dental practitioners in the region, regardless of whether they are a GP or a specialist."
Tuesday, 19 November, 2024